Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.270
+0.005 (0.40%)
At close: Aug 7, 2026, 4:00 PM EDT
1.350
+0.080 (6.30%)
Pre-market: Aug 10, 2026, 7:00 AM EDT
Coherus Oncology Employees
Coherus Oncology had 145 employees as of March 31, 2026. The number of employees decreased by 76 or -34.39% compared to the same quarter last year.
Employees
145
Change
-76
Growth
-34.39%
Revenue / Employee
$351,283
Profits / Employee
-$911,255
Market Cap
196.22M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 145 | -76 | -34.39% |
| Dec 31, 2025 | 147 | -81 | -35.53% |
| Sep 30, 2025 | 158 | -77 | -32.77% |
| Jun 30, 2025 | 177 | -69 | -28.05% |
| Mar 31, 2025 | 221 | -28 | -11.24% |
| Dec 31, 2024 | 228 | -78 | -25.49% |
| Sep 30, 2024 | 235 | -64 | -21.40% |
| Jun 30, 2024 | 246 | -48 | -16.33% |
| Mar 31, 2024 | 249 | -58 | -18.89% |
| Dec 31, 2023 | 306 | -53 | -14.76% |
| Sep 30, 2023 | 299 | -77 | -20.48% |
| Jun 30, 2023 | 294 | -74 | -20.11% |
| Mar 31, 2023 | 307 | -39 | -11.27% |
| Dec 31, 2022 | 359 | 27 | 8.13% |
| Sep 30, 2022 | 376 | 42 | 12.57% |
| Jun 30, 2022 | 368 | 57 | 18.33% |
| Mar 31, 2022 | 346 | 36 | 11.61% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Invivyd | 122 |
| Arcturus Therapeutics Holdings | 111 |
| Immunic | 95 |
| Keros Therapeutics | 87 |
| AN2 Therapeutics | 21 |
| Galectin Therapeutics | 9 |
| Greenwich LifeSciences | 8 |
CHRS News
- 2 days ago - Coherus Oncology price target lowered to $10 from $12 at Guggenheim - TheFly
- 4 days ago - Coherus Oncology reports Q2 EPS (19c), consensus (12c) - TheFly
- 4 days ago - Coherus Oncology Earnings Call Transcript: Q2 2026 - Transcripts
- 4 days ago - Coherus Oncology Earnings release: Q2 2026 - Filings
- 4 days ago - Coherus Oncology Quarterly report: Q2 2026 - Filings
- 4 days ago - Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 18 days ago - Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 - GlobeNewsWire
- 6 weeks ago - Coherus, Zumutor collaborate for ZM008, Loqtorzi combination study - TheFly